|
Correlations with clinical and laboratory parameters of anti-CCP antibody-positive and -negative primary Sjögren syndrome patients |
|||
| Anti-CCP-positive (n = 14) |
Anti-CCP-negative (n = 127) |
P value |
|
|
|
|||
| Age (range), years |
41 (34.5–52.2) |
49 (39–60) |
0.134 |
| Disease duration, years |
2.4 (1.40–7.5) |
2.5 (0.98–5.2) |
0.415 |
| Synovitis, number (percentage) |
12 (85.7) |
32 (25.2) |
<0.001 |
| Extra-glandular involvement, number (percentage) |
9 (64.3) |
72 (56.7) |
0.777 |
| Erythrocyte sedimentation rate (range), mm/1st hour |
34 (24.25–45.5) |
27 (16.5–38) |
0.101 |
| Rheumatoid factor, number (percentage) |
10 (71.4) |
84 (66.1) |
0.774 |
| Anti-nuclear antibodies, number (percentage) |
13 (92.9) |
121 (95.3) |
0.527 |
| Anti-La (SSB) antibodies, number (percentage) |
10 (71.4) |
105 (82.7) |
0.291 |
| Anti-Ro (SSA) antibodies, number (percentage) |
6 (42.9) |
49 (38.6) |
0.779 |
| Focus score of greater than 1, number (percentage) |
9 (64.3) |
85 (67.5) |
0.773 |
|
Anti-CCP, cyclic citrullinated peptide antibody. | |||
Atzeni et al. Arthritis Research & Therapy 2008 10:R51 doi:10.1186/ar2420 |
|||